Woo yul Lee

Dr. Woo yul Lee

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
HPHyeonsoo Park
Hyeonsoo Park
CKChoon Ok Kim
Choon Ok Kim
MKMikyung Kim
Mikyung Kim
YLYeji Lim
Yeji Lim
WLWoo yul Lee
Woo yul Lee
MPMin Soo Park
Min Soo Park
Park H, et al. Transl Clin Pharmacol. 2020 Sep;28:e16. /Synapse/10.12793/tcp.2020.28.e16

1 January 2020 in Translational and Clinical Pharmacology
Verified
Journal Article
Open access
WLWoo yul Lee
Woo yul Lee
EOEunSil Oh
EunSil Oh
MCMengqi Cui
Mengqi Cui
CKChoon Ok Kim
Choon Ok Kim
YLYeji Lim
Yeji Lim
THTaegon Hong
Taegon Hong
Lee WY, et al. Transl Clin Pharmacol. 2020 Mar;28:e5. /Synapse/10.12793/tcp.2020.28.e5

3 May 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
WLWoo yul Lee
Woo yul Lee
DCDongwoo Chae
Dongwoo Chae
CKChoon Ok Kim
Choon Ok Kim
SLSang Eun Lee
Sang Eun Lee
YKYee Gyung Kwak
Yee Gyung Kwak
KPKyungsoo Park
Kyungsoo Park
While primaquine has long been used for malaria treatment, treatment failure is common. This study aims to develop a population pharmacokinetic model of primaquine and its metabolite, carboxyprimaquine, and examine factors influencing pharmacokinetic variability. The data was obtained from a clinical study in 24 Korean subjects randomly assigned to normal and obese groups. The participants received primaquine 15 mg daily for 4 days and blood samples were collected at day 4. Pharmacokinetic modeling was performed with NONMEM and using simulations; the influences of doses and covariates on drug exposure were examined. A minimal physiology-based pharmacokinetic model connected with a liver compartment comprehensively described the data, with CYP450 mediated clearance being positively correlated with the body weight and CYP2D6 activity score (p < 0.05). In the simulation, while the weight-normalized area under drug concentration for primaquine in the obese group decreased by 29% at the current recommended dose of 15 mg, it became similar to the normal weight group at a weight-normalized dose of 3.5 mg/kg. This study has demonstrated that the body weight and CYP2D6 activity score significantly influence the pharmacokinetics of primaquine. The developed model is expected to be used as a basis for optimal malaria treatment in Korean patients.